2892 Pentazocine Pentazocine is an exogenous solid with the formula C19H27NO and an average molecular weight of 285.42 g/mol. Pentazocine belongs to the 2,6-dimethyl-3-benzazocines, a subclass of 6,7-benzomorphans within the organic compounds. This compound is recorded as being found in or released from five sources: analgesics within healthcare, pharmaceuticals, and veterinary products; non-electric simulated smoking devices and other smoking requisites within household cleaning and consumer products; and antennas and radio transmission systems within electrical and electronic equipment. Recorded exposure routes include intramuscular, intravenous, oral, and subcutaneous administration. The compound interacts with four recorded protein targets: the mu-type opioid receptor (OPRM1), kappa-type opioid receptor (OPRK1), sigma non-opioid intracellular receptor 1 (SIGMAR1), and delta-type opioid receptor (OPRD1). The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. 359-83-1 441278 C19H27NO 285.209260 White powder. 146.3°C 1.22e-01 g/L Intravenous, Oral. Well absorbed from the gastro-intestinal tract. The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Hepatic Half Life: 2 to 3 hours No indication of carcinogenicity to humans (not listed by IARC). Used to treat mild to moderately severe pain. [Wikipedia] Medical problems can include congested lungs, liver disease, tetanus, cardiovascular effects, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose. hallucinations and other psychotomimetic effects; cardiovascular effects Adequate measures to maintain ventilation and general circulatory support should be employed. Assisted or controlled ventilation, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Consideration should be given to gastric lavage and gastric aspiration. For respiratory depression due to overdosage or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist. Initial doses of 0.4 to 2.0 mg of naloxone are recommended, repeated at 2-3 minute intervals, if needed, up to a total of 10 mg. Anti 2009-07-21T20:27:20Z 2026-05-14T16:45:07Z Pentazocine C07421 116117 Pentazocine DB00652 true C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C C19H27NO InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1 VOKSWYLNZZRQPF-GDIGMMSISA-N 285.4238 285.209264491 Exogenous Solid 4.64 HMDB14790 CHEMBL560 390041 CHEM002239 DTXSID7023433 1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-trien-4-ol 23.47 89.7993 33.86191659961722 2 2 1 7.590926857289439 12.401294420402692 1 3 4.44 -3.37 1.22e-01 g/l Organic compounds Alkaloids and derivatives 6,7-benzomorphans 2,6-dimethyl-3-benzazocines 3141 CED0004344 VOKSWYLNZZRQPF-GDIGMMSISA-N 8000000000000000000000001000000020000100000000000000000000000000000000000004000000000008000000000001000000000000000000000000080000000008000000000000000002000000000000400000000000000100000000000000001000000000000201000000000000000000015200000000480000000000000000000000002000000000000000000802004000200000000c4000000000000000080000000000000000000000008000010000000000000000000a00002020000000000000000000400000000000000200000000000000000000000000200040080000000000000000000000080000000002000200 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 776t3gAAAAAQAAAAAwAAAAAAAAAVAAAAFwAAAIABBgBgAAAAAQMGIDQAAAAB AQQGIDQAAAABAQQGAGAAAAACAgZAKAAAAAMEBkBoAAAAAwMBBkBoAAAAAwMB BkAoAAAAAwQIAGgAAAADAQEGQGgAAAADAwEGQCgAAAADBAYgJAAAAAIEBgBg AAAAAQMGAGAAAAACAgYAYAAAAAICBwAgAAAAAwYAYAAAAAICBgBoAAAAAwMB BgAoAAAAAwQGAGAAAAABAwYAYAAAAAEDCwABAAECAAIDAAMEAAQFaAwFBmgM BgdoDAcIIAcJaAwJCmgMCgsACwwACw0ADQ4ADg8ADxAAEBEAERIIAhITABIU AAsBAA8CAAoEaAxCAwAAAAYBCwoEAwIGAQsNDg8CBgUGBwkKBBcEAAAAAAAA ABY= 2026-09-19T04:00:36Z